- cafead Jun 03, 2021 at 11:22: PM
via Since 2017, Pfizer’s kinase inhibitor Sutent has been approved to help prevent tumors from returning in high-risk kidney cancer patients after surgery. But its efficacy and safety are far from ideal.
Now, Merck & Co. hopes to set a new standard of care with its PD-1 inhibitor Keytruda.
article source
Now, Merck & Co. hopes to set a new standard of care with its PD-1 inhibitor Keytruda.
article source